Nano-Cap MIRA Pharmaceuticals' Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders
Portfolio Pulse from Vandana Singh
MIRA Pharmaceuticals Inc (NASDAQ:MIRA) announced promising preclinical results for its novel oral ketamine analog, Ketamir-2, which shows potential in treating neuropsychiatric disorders. The company plans to submit an IND application to the FDA by the end of the year. Ketamir-2 demonstrates better oral bioavailability and fewer side effects compared to traditional ketamine. MIRA's stock surged 151.20% to $1.73 following the announcement.
July 22, 2024 | 2:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceuticals announced promising preclinical results for its oral ketamine analog, Ketamir-2, which shows potential in treating neuropsychiatric disorders. The company plans to submit an IND application to the FDA by the end of the year. MIRA's stock surged 151.20% to $1.73 following the announcement.
The announcement of promising preclinical results for Ketamir-2, a novel oral ketamine analog, is a significant development for MIRA Pharmaceuticals. The potential for better efficacy and fewer side effects compared to traditional ketamine, along with the upcoming IND application, has driven investor optimism, resulting in a substantial stock price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100